Quality-first, Business-perspective, Long-term, Urbem (HK) Limited

Urbem Capital

Quality-first, Business-perspective, Long-term

Quality-first, Business-perspective Strategy

Urbem (HK) Limited

Equity Bottom-Up

Perfect Medical Health Management / Equity Bottom-Up

Perfect Medical Health Management (1830 HK)

<ul>
<li>Our 2020 thesis correctly identified Perfect Medical’s cash generation and management discipline, but underestimated how narrow and execution-dependent its moat was.</li>
<li>The full financial history shows resilience rather than compounding: overseas expansion disappointed, margins compressed sharply, and competitive pressure remained persistent.</li>
<li>At roughly 9x FY03/2026 earnings with an 11% trailing dividend yield, the stock is interesting again - but the thesis is now stabilization and cash return.</li>
</ul>


Our 2020 thesis correctly identified Perfect Medical’s cash generation and management discipline, but underestimated how narrow and execution-dependent its moat was.
The full financial history shows resilience rather than compounding: overseas expansion disappointed, margins compressed sharply, and competitive pressure remained persistent.
At roughly 9x FY03/2026 earnings with an 11% trailing dividend yield, the stock is interesting again - but the thesis is now stabilization and cash return.


Perfect Medical Revisited: What Worked, What Did Not, and What 9x Earnings Means Today

Equity, Bottom-up Analyst, Investics Research

Sameer Taneja

Equity, Bottom-up Analyst

Investics Research

It is important to note that the information provided by Investics Research is based on publicly available data and own knowledge, which has been gathered and analyzed from a variety of sources. While every effort has been made to ensure the accuracy and completeness of the information provided, it is not guaranteed to be free from errors or omissions. All forecasts and estimates are based on information that has been obtained from public sources that are considered to be reliable. The sources include but are not limited to, company announcements, exchange filings, presentations, etc. Investics does not guarantee the accuracy and completeness of the forecasts, estimates, and/or other information.

Equity Bottom-up Research

<ul>
<li>
<a href="https://www.smartkarma.com/entities/perfect-medical-health-management-limited" target="_blank" data-smartkarma-citation="entities:3639:1" rel="noopener">Perfect Medical Health Management (1830 HK)</a>  reported FY26 revenue of HKD 962.3mn (-14.7% YoY) and net profit attributable of HKD 178.7mn (-13.6% YoY), with improving H2 results on stabilizing sentiment. </li>
<li>The story is the H2 inflection, where revenue fell 6.1% YoY (vs -21.7% in H1), while H2 net profit rose 27.1% period-on-period to HKD 83.9mn, driven by cost cuts.</li>
<li>Debt-Free, cash-rich (~HKD 523mn cash + investments) and holding a 100%+ payout for an 11th straight year (FY26 payout 102.8%), the stock offers a ~12.6% yield at ~8.2x P/E.</li>
</ul>



Perfect Medical Health Management (1830 HK)  reported FY26 revenue of HKD 962.3mn (-14.7% YoY) and net profit attributable of HKD 178.7mn (-13.6% YoY), with improving H2 results on stabilizing sentiment. 
The story is the H2 inflection, where revenue fell 6.1% YoY (vs -21.7% in H1), while H2 net profit rose 27.1% period-on-period to HKD 83.9mn, driven by cost cuts.
Debt-Free, cash-rich (~HKD 523mn cash + investments) and holding a 100%+ payout for an 11th straight year (FY26 payout 102.8%), the stock offers a ~12.6% yield at ~8.2x P/E.


Perfect Medical (1830 HK): H2 Turnaround as Cost Discipline Lifts Margins; Watch the Demand Recovery

<ul>
<li>
<a href="https://www.smartkarma.com/entities/perfect-medical-health-management-limited" target="_blank" data-smartkarma-citation="entities:3639:1" rel="noopener">Perfect Medical Health Management (1830 HK)</a> has had a tough last two years, with profits/revenues falling 31%/44%, respectively, from FY24 to FY26 as the retail environment in HK was soft. </li>
<li>The last few quarters have seen revenue stabilization and, more recently, a gradual improvement, as the company has flagged in its post-results report (with cost savings gradually kicking in).</li>
<li>We now estimate a modest 7%/14% revenue/profit growth for FY27, with net margin improvement to 20%. Stock trades at 7.8x FY27 PE with a 13.5% dividend yield and net cash.  </li>
</ul>



Perfect Medical Health Management (1830 HK) has had a tough last two years, with profits/revenues falling 31%/44%, respectively, from FY24 to FY26 as the retail environment in HK was soft. 
The last few quarters have seen revenue stabilization and, more recently, a gradual improvement, as the company has flagged in its post-results report (with cost savings gradually kicking in).
We now estimate a modest 7%/14% revenue/profit growth for FY27, with net margin improvement to 20%. Stock trades at 7.8x FY27 PE with a 13.5% dividend yield and net cash.  


Perfect Medical (1830 HK): Firming Up Outlook For FY27, Improving HK Retail Beneficiary

<ul>
<li>If <a href="https://www.smartkarma.com/entities/perfect-medical-health-management" target="_blank" data-smartkarma-citation="entities:3639:1" rel="noopener">Perfect Medical Health (1830 HK)</a> replicates in H1FY26 earnings, a 15 HKD cent dividend implies a 12.5% dividend yield on the current share price (100% payout ratio). </li>
<li>The semi‑annual results suggest modest improvement in retail sales, though management of most firms (except Flameglow 8603 HK) remain guarded in their outlooks. </li>
<li>In order of preference, currently <a href="https://www.smartkarma.com/entities/water-oasis-group-ltd" target="_blank" data-smartkarma-citation="entities:17348:1" rel="noopener">Water Oasis (1161 HK)</a> seems the safest bet, followed by <a href="https://www.smartkarma.com/entities/perfect-medical-health-management" target="_blank" data-smartkarma-citation="entities:3639:1" rel="noopener">Perfect Medical Health (1830 HK)</a>. While Flameglow's growth is good, margins are a question mark.</li>
</ul>


If Perfect Medical Health (1830 HK) replicates in H1FY26 earnings, a 15 HKD cent dividend implies a 12.5% dividend yield on the current share price (100% payout ratio). 
The semi‑annual results suggest modest improvement in retail sales, though management of most firms (except Flameglow 8603 HK) remain guarded in their outlooks. 
In order of preference, currently Water Oasis (1161 HK) seems the safest bet, followed by Perfect Medical Health (1830 HK). While Flameglow's growth is good, margins are a question mark.


Medical Beauty Plays in Hong Kong: Perfect/Water Oasis and Flameglow: A Better Retail Environment?

Plover Bay Technologies / Equity Bottom-Up

<ul>
<li>The screen isolates eight Hong Kong-listed companies with a five-year average ROCE above 15% (median 33.0%), spanning exchanges, medical aesthetics, toys, apparel, and networking hardware.</li>
<li>Capital efficiency converts into cash: all eight have paid dividends every year since FY20, with a median trailing yield of 7.7% and cumulative payouts near half the average share price.</li>
<li>Valuations remain undemanding: six of eight trades trade below 11x earnings and 6x EV/EBITDA, leaving Taste Gourmet, JNBY, and Dream International the best risk-reward.</li>
</ul>


The screen isolates eight Hong Kong-listed companies with a five-year average ROCE above 15% (median 33.0%), spanning exchanges, medical aesthetics, toys, apparel, and networking hardware.
Capital efficiency converts into cash: all eight have paid dividends every year since FY20, with a median trailing yield of 7.7% and cumulative payouts near half the average share price.
Valuations remain undemanding: six of eight trades trade below 11x earnings and 6x EV/EBITDA, leaving Taste Gourmet, JNBY, and Dream International the best risk-reward.


HK High ROCE - Compounders Hiding in Plain Sight

Hong Kong

Perfect Medical Health Management is an investment holding company primarily engaged in providing medical health and medical beauty services. The company offers a comprehensive range of non-invasive medical and aesthetic services, including personalized medical aesthetic solutions, hair growth treatments, pain management, preventive care, and reproductive medical services. It operates across Hong Kong, Macau, Mainland China, Australia, and Singapore. The company was incorporated on March 11, 2011, and is headquartered in Hong Kong.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Perfect Medical Health Management (1830 HK)

Perfect Medical Revisited: What Worked, What Did Not, and What 9x Earnings Means Today

Six years on, Perfect Medical looks less like the compounder we once envisioned and more like a resilient cash-return story whose narrow moat is...

Urbem Capital

Perfect Medical (1830 HK): H2 Turnaround as Cost Discipline Lifts Margins; Watch the Demand Recovery

Perfect Medical FY26: H2 net profit +27% as cost cuts and a stable HK store base drive a turnaround. Debt-free, 102.8% payout, ~12.5% yield;...

Sameer Taneja

Perfect Medical (1830 HK): Firming Up Outlook For FY27, Improving HK Retail Beneficiary

At 7.8x with a 13.5% yield and net cash, Perfect Medical looks mispriced. The H2 FY26 profit inflection and margin recovery to ~20% set up a re...

Sameer Taneja

Medical Beauty Plays in Hong Kong: Perfect/Water Oasis and Flameglow: A Better Retail Environment?

We contrast all the beauty plays in HK, i.e., Water Oasis, Perfect Medical, Flameglow, and EC healthcare. We provide commentary on their recent...

Sameer Taneja

HK High ROCE - Compounders Hiding in Plain Sight

Eight HK-listed names with a 33% median ROCE, annual dividends since FY20, and a 9.4x median P/E. Median total return: 214% since 2020. Best value:...

Sameer Taneja

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)